2024年1月10日 · Actinium-225 (225 Ac) prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) is a novel therapy for metastatic castration-resistant prostate cancer (mCRPC). We aimed to report the safety and antitumour activity of 225 Ac-PSMA RLT of mCRPC in a large cohort of patients treated at multiple centres across the world.

Actinium-225 (Ac-225) labelled PSMA RLT has been tested recently in metastatic castration-resistant prostate cancer (mCRPC), with encouraging results. Ac-225, being an alpha emitter, is expected to have higher efficacy and fewer side effects compared to …

Therefore, beta and alpha radionuclide therapy (RNT) have emerged as novel treatment options for patients with mCRPC. Radioligands target the prostate-specific membrane antigen (PSMA) epitopes, which are upregulated up to a thousand times more in prostate cancer cells compared to the cells in normal tissues.

Background: Actinium-225 (225 Ac) prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) is a novel therapy for metastatic castration-resistant prostate cancer (mCRPC). We aimed to report the safety and antitumour activity of 225 Ac-PSMA RLT of mCRPC in a large cohort of patients treated at multiple centres across the world.

2022年8月20日 · In the past few years, alpha-emitting radionuclides have been expected to enhance therapeutic effects by inducing more DNA double-strand breaks than beta-emitting radionuclides. Several alpha emitters, such as 225 Ac and 213 Bi, have been investigated as targeted alpha therapy (TAT) for PSMA RLT. 225 Ac-labeled PSMA

2021年3月1日 · Beta-emitting Lu-177-labeled prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) is a new option for metastatic castration-resistant prostate cancer (mCRPC), but its antitumor effect can decrease over time. To report the safety and activity of alpha-emitting Ac-225-PSMA-617 RLT in mCRPC that has progressed after Lu-177-PSMA.

2025年3月4日 · 3月3日，全球临床试验收录网站显示，诺华启动了新一代放射配体疗法（RLT）AAA817（ [225Ac]Ac-PSMA-617）的III期临床试验（AcTFirst）。 该研究是一项多中心、随机、开放标签、阳性药物对照临床试验（n=486），旨在评估AAA817联合雄激素受体信号通路抑制剂（ARPI）对比研究者选择的标准治疗（SoC）治疗未接受过含紫杉醇化疗方案和RLT治疗的PSMA阳性转移性去势抵抗性前列腺癌（mCRPC）患者的有效性和安全性。 研究的主要终点 …

2025年3月5日 · 3月3日，全球临床试验收录网站显示，诺华启动了新一代放射配体疗法（RLT）AAA817（ [225Ac]Ac-PSMA-617）的III期临床试验（AcTFirst）。 该研究是一项多中心、随机、开放标签、阳性药物对照临床试验（n=486），旨在评估AAA817联合雄激素受体信号通路抑制剂（ARPI）对比 ...

2021年3月21日 · With its high linear energy transfer and short path length, 225 Ac induces double-stranded DNA breaks and is expected to have excellent efficacy and safety profile. This systematic review was...

Here comes the emerging role of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (PRLT) as a promising treatment modality for managing mCRPC. Several small-molecule PSMA ligands that can be conjugated to radioisotopes, such as 18 F, 68 Ga, 177 Lu, and 225 Ac, among others, have been developed [3].